Mirum Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was -1,135.46%. Mirum Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 17.50.
Mirum Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -64.88%.
Mirum Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Mirum Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Mirum Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals ROE % Adjusted to Book Value Chart
MEX:MIRM vs RYTM, SYRE, PTGX: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -64.88% mean?
Mirum Pharmaceuticals (MEX:MIRM) has a ROE % Adjusted to Book Value of -64.88% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' ROE % Adjusted to Book Value too high?
Mirum Pharmaceuticals' current ROE % Adjusted to Book Value is -64.88%. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' ROE % Adjusted to Book Value compare to RYTM and SYRE?
Mirum Pharmaceuticals' ROE % Adjusted to Book Value of -64.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current ROE % Adjusted to Book Value is -64.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current ROE % Adjusted to Book Value of -64.88%. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current ROE % Adjusted to Book Value is -64.88%. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current ROE % Adjusted to Book Value is -64.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.
Key valuation signals for MEX:MIRM:
ROE % Adjusted to Book Value: -64.88%
GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score
Get the complete analysis for MEX:MIRM
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MIRM has been successfully added to your 
